Cardiovascular Morbidity and Pure Red Cell Aplasia Associated with Epoetin Theta Therapy in Patients with Chronic Kidney Disease: A Prospective, Noninterventional, Multicenter Cohort Study

Clinical Therapeutics

Volumn 38, Issue 2, 2016, Pages 276-287.e4

  Lammerich, Andreas ^a   Balcke, Peter ^b   Bias, Peter ^a   Mangold, Simone ^a   Wiesholzer, Martin ^b  

^a TEVA PHARMACEUTICALS   (Israel)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

adverse reaction; anemia; cardiovascular morbidity; chronic kidney disease; epoetin theta; safety; tolerability

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT; ERYTHROPOIETIN;

AGED; ANEMIA; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSIVE CRISIS; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POST HOC ANALYSIS; PRACTICE GUIDELINE; PROSPECTIVE STUDY; PURE RED CELL ANEMIA; REVIEW; SHUNT THROMBOSIS; ADOLESCENT; ADULT; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPLICATION; MIDDLE AGED; MYOCARDIAL INFARCTION; RED-CELL APLASIA, PURE; STROKE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; COHORT STUDIES; ERYTHROPOIETIN; FEMALE; HEART FAILURE; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; RED-CELL APLASIA, PURE; RENAL INSUFFICIENCY, CHRONIC; STROKE; YOUNG ADULT;

EID: 84950121471     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2015.11.018     Document Type: Article

References (25)

1. J.W. Eschbach, and J.W. Adamson Anemia of end-stage renal disease (ESRD) Kidney Int 28 1985 1 5
2. W.H. Kazmi, A.T. Kausz, S. Khan, and et al. Anemia: an early complication of chronic renal insufficiency Am J Kidney Dis 38 2001 803 812
3. B.C. Astor, P. Muntner, A. Levin, and et al. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994) Arch Intern Med 162 2002 1401 1408
4. A.S. Levey, and J. Coresh Chronic kidney disease Lancet 379 2012 165 180
5. L. Del Vecchio, and F. Locatelli Anemia in chronic kidney disease patients: treatment recommendations and emerging therapies Expert Rev Hematol 7 2014 495 506
6. W. McClellan, S.L. Aronoff, W.K. Bolton, and et al. The prevalence of anemia in patients with chronic kidney disease Curr Med Res Opin 20 2004 1501 1510
7. US Renal Data System. USRDS 2006 Annual Data Reports: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md, 2006. http://www.usrds.org/atlas06.aspx. Accessed 25 October 2015.
8. A. Al-Ahmad, W.M. Rand, G. Manjunath, and et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction J Am Coll Cardiol 38 2001 955 962
9. W.M. McClellan, W.D. Flanders, R.D. Langston, and et al. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study J Am Soc Nephrol 13 2002 1928 1936
10. A.J. Collins The hemoglobin link to adverse outcomes Adv Stud Med 3 2003 S194 S197
11. A. Besarab, W.K. Bolton, J.K. Browne, and et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin N Engl J Med 339 1998 584 590
12. T.B. Drüeke, F. Locatelli, N. Clyne, and et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia N Engl J Med 355 2006 2071 2084
13. A.K. Singh, L. Szczech, K.L. Tang, and et al. Correction of anemia with epoetin alfa in chronic kidney disease N Engl J Med 355 2006 2085 2098
14. M.A. Pfeffer, E.A. Burdmann, C.Y. Chen, and et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease N Engl J Med 361 2009 2019 2032
15. E.F. Unger, A.M. Thompson, M.J. Blank, and R. Temple Erythropoiesis-stimulating agents - time for a reevaluation N Engl J Med 362 2010 189 192
16. B.D. Hedley, A.L. Allan, and A. Xenocostas The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression Clin Cancer Res 17 2011 6373 6380
17. Kidney Disease Improving Global Outcomes KDIGO clinical practice guideline for anemia in chronic kidney disease Kidney Int 2 2012 279 335
18. N. Casadevall, K.U. Eckardt, and J. Rossert Epoetin-induced autoimmune pure red cell aplasia J Am Soc Nephrol 16 Suppl 1 2005 S67 S99
19. Amgen. Background information for the joint meeting between the Cardiovascular And Renal Drugs Advisory Committee & Drug Safety And Risk Management Advisory Committee, 11 September 2007. Safety and efficacy of erythropoiesis-stimulating agents (ESAs) in chronic renal failure. 8 August 2007. http://www.amgen.com/pdfs/misc/2007-AMGEN-FDA-CADRC.pdf. Accessed 25 October 2015.
20. International Conference on Harmonisation. Guidance for Industry. Good Clinical Practice: Consolidated Guidance. April 1996. http://www.fda.gov/downloads/Drugs/./Guidances/ucm073122.pdf. Accessed 25 October 2015.
21. S. Fishbane, and A. Besarab Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets Clin J Am Soc Nephrol 2 2007 1274 1282
22. K.J. Smith, A.J. Bleyer, W.C. Little, and D.C. Sane The cardiovascular effects of erythropoietin Cardiovasc Res 59 2003 538 548
23. T. Drüeke Hyporesponsiveness to recombinant human erythropoietin Nephrol Dial Transplant 16 2001 25 28
24. A. Icardi, E. Paoletti, L. De Nicola, and et al. Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: the potential role of inflammation Nephrol Dial Transplant 28 2013 1672 1679
25. P.A. McCullough, H.X. Barnhart, J.K. Inrig, and et al. Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease Am J Nephrol 37 2013 549 558